The short answer
Amycretin is a unimolecular agonist of both the GLP-1 and amylin receptors developed by Novo Nordisk. Unlike CagriSema, which combines two separate molecules, amycretin engages both receptors from a single peptide. It exists in once-weekly subcutaneous and once-daily oral forms, and Phase 2 data reported up to 14.5% weight reduction at 36 weeks.
Key facts
- Class
- Unimolecular GLP-1 + amylin receptor agonist
- Developer
- Novo Nordisk
- Formulations
- Weekly subcutaneous and daily oral
- Phase 2 population
- 448 adults with type 2 diabetes
- Duration
- Up to 36 weeks
- Subcutaneous result
- 11.9% placebo-adjusted reduction
- Oral result
- 7.6% placebo-adjusted reduction
- Status
- Advancing to Phase 3
Unimolecular versus combination
This is the technically interesting part. CagriSema achieves amylin and GLP-1 agonism by putting two engineered peptides in one syringe. Amycretin achieves it with one peptide that binds both receptors. Unimolecular design removes the need to match the pharmacokinetics of two separate agents and simplifies manufacturing, but it is a much harder molecule to engineer, the same problem that makes retatrutide's triple agonism notable.
What the Phase 2 trial tested
The study enrolled 448 adults with type 2 diabetes inadequately controlled on metformin, with or without an SGLT2 inhibitor. It was a combined multiple-ascending-dose design testing six weekly subcutaneous doses from 0.4 mg to 40 mg and three daily oral doses of 6 mg, 25 mg and 50 mg, over up to 36 weeks.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
The results, and the detail worth noticing
Weight reduction reached up to 14.5% at 36 weeks against placebo, with the weekly subcutaneous formulation producing 11.9% placebo-adjusted reduction and the daily oral form 7.6%. The finding that attracted most attention was not the headline figure: at the higher doses, no weight-loss plateau had been reached by week 36 in either route. A curve that has not flattened at the end of a trial says the observed number is a floor for that duration, not a ceiling.
Tolerability
Adverse events were predominantly gastrointestinal and mostly mild to moderate, consistent with both the incretin and amylin classes. The profile was described as safe and well tolerated across both routes, though Phase 2 populations are small relative to what a full safety picture requires.
Why an oral form matters here
Amycretin is a peptide, so its daily oral form faces the same barriers that make oral peptides difficult: gastric acid, proteases, poor permeability. That an oral peptide route produced 7.6% placebo-adjusted reduction at all is the notable part, and it sits in direct contrast to orforglipron's approach of abandoning the peptide backbone entirely.
Frequently asked questions
How is amycretin different from CagriSema?
CagriSema is two molecules combined. Amycretin is one molecule that binds both receptors, which is harder to design but avoids having to match two pharmacokinetic profiles.
Is amycretin approved anywhere?
No. It completed Phase 2 and is advancing into Phase 3.
Why does 'no plateau at week 36' matter?
It means weight reduction was still continuing when the trial ended, so the reported figure reflects the trial's length rather than the compound's limit.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- What Is an Amylin Receptor Agonist?Amylin is a 37-residue hormone co-secreted with insulin. How amylin receptor agonists signal satiety through the area postrema, and why they pair with GLP-1.
- Glucagon-Containing Dual Agonists: Survodutide and MazdutideWhy adding glucagon-receptor activity raises energy expenditure and targets liver fat. Survodutide and mazdutide trial status, and the counterintuitive logic.
- What the Data Says About Weight Regain After StoppingSTEP-1 extension found about two-thirds of lost weight returned within a year of stopping semaglutide. Meta-analyses put regain at roughly 0.8 kg per month.
- How to Read a Weight-Loss Trial Result ProperlyEstimands, populations, durations and discontinuation rates. Why CagriSema reports both 22.7% and 20.4%, and why headline percentages are not comparable.
- Oral Semaglutide vs OrforglipronBoth are tablets, only one is a peptide. Why oral semaglutide needs SNAC and a fasting window while orforglipron needs neither, and what that costs each.